HKU Scholars Hub: Browsing DSpace

Browsing by Author El-Khoueiry, AB

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 7 of 7

	Title	Author(s)	Issue Date	Views
	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial Journal:JAMA Oncology	Yau, TCC Kang, YK Kim, TY El-Khoueiry, AB Santoro, A Sangro, B Melero, I Kudo, M Hou, MM Matilla, A Tovoli, F Knox, JJ He, AR El-Rayes, BF Acosta-Rivera, M Lim, HY Neely, J Shen, Y Wisniewski, T Anderson, J Hsu, C	2020	70
	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017	151
	Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study Proceeding/Conference:Liver Cancer	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Welling, TH, III Yeo, W Chopra, A Anderson, J dela Cruz, C Lang, L Neely, J Melero, I	2016	64
	Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study Proceeding/Conference:Liver Cancer	Sangro, B Melero, I Yau, TCC Hsu, C Kudo, M Crocenzi, TS Kim, TY Choo, SP Trojan, J Meyer, T Kang, YK Anderson, J dela Cruz, C Lang, L Neely, J El-Khoueiry, AB	2016	151
	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial Journal:ESMO Open	Kelley, RK Ryoo, BY Merle, P Park, JW Bolondi, L Chan, SL Lim, HY Baron, AD Parnis, F Knox, J Cattan, S Yau, T Lougheed, JC Milwee, S El-Khoueiry, AB Cheng, AL Meyer, T Abou-Alfa, GK	2020	29
	Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma Journal:Clinical Cancer Research	Kelley, RK Meyer, T Rimassa, L Merle, P Park, JW Yau, T Chan, SL Blanc, JF Tam, VC Tran, A Dadduzio, V Markby, DW Kaldate, R Cheng, AL El-Khoueiry, AB Abou-Alfa, GK	2020	32
	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Journal:Journal for ImmunoTherapy of Cancer	Greten, TF Abou-Alfa, GK Cheng, AL Duffy, AG El-Khoueiry, AB Finn, RS Galle, PR Goyal, L He, AR Kaseb, AO Kelley, RK Lencioni, R Lujambio, A Mabry Hrones, D Pinato, DJ Sangro, B Troisi, RI Wilson Woods, A Yau, T Zhu, AX Melero, I	2021	24

Showing results 1 to 7 of 7